Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.